Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer

[1]  R. De Maria,et al.  The Hippo pathway in normal development and cancer , 2018, Pharmacology & therapeutics.

[2]  G. Ciliberto,et al.  Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy , 2018, Journal of Translational Medicine.

[3]  E. Gallo,et al.  DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first‐line chemotherapy , 2017, International journal of cancer.

[4]  G. Blandino,et al.  Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers , 2017, International journal of molecular sciences.

[5]  A. Maitra,et al.  β-Catenin destruction complex-independent regulation of Hippo–YAP signaling by APC in intestinal tumorigenesis , 2015, Genes & development.

[6]  I. Vitale,et al.  The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications , 2015, Expert Reviews in Molecular Medicine.

[7]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[8]  Giuseppe Basso,et al.  YAP/TAZ Incorporation in the β-Catenin Destruction Complex Orchestrates the Wnt Response , 2014, Cell.

[9]  H. Ji,et al.  A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. , 2014, Cancer cell.

[10]  Jun Yu,et al.  Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis , 2011, Clinical Cancer Research.

[11]  Rascon.  [The National Cancer Institute]. , 1953, Boletin cultural e informativo - Consejo General de Colegios Medicos de Espana.